Sotera Health (NASDAQ:SHC) Insider Michael Rutz Sells 150,000 Shares of Stock

Sotera Health Company (NASDAQ:SHC) insider Michael Rutz sold 150,000 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $18.84, for a total value of $2,826,000.00. Following the completion of the transaction, the insider owned 334,279 shares of the company’s stock, valued at $6,297,816.36. The trade was a 30.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Sotera Health Price Performance

Shares of NASDAQ SHC traded up $0.14 during mid-day trading on Tuesday, hitting $19.11. 3,706,496 shares of the stock traded hands, compared to its average volume of 2,891,297. The company has a market cap of $5.45 billion, a PE ratio of 33.53 and a beta of 1.77. Sotera Health Company has a twelve month low of $13.09 and a twelve month high of $19.85. The company has a debt-to-equity ratio of 3.33, a current ratio of 2.80 and a quick ratio of 2.55. The firm has a 50 day simple moving average of $17.20 and a two-hundred day simple moving average of $16.31.

Sotera Health (NASDAQ:SHC) last issued its earnings results on Thursday, August 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.02. The business had revenue of $321.38 million during the quarter, compared to analysts’ expectations of $309.70 million. Sotera Health had a return on equity of 40.12% and a net margin of 13.44%.The business’s revenue for the quarter was up 9.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.20 EPS. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. As a group, equities research analysts forecast that Sotera Health Company will post 0.87 EPS for the current fiscal year.

Hedge Funds Weigh In On Sotera Health

Several hedge funds and other institutional investors have recently bought and sold shares of SHC. Empowered Funds LLC lifted its stake in shares of Sotera Health by 11.1% in the 1st quarter. Empowered Funds LLC now owns 28,512 shares of the company’s stock valued at $332,000 after purchasing an additional 2,845 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Sotera Health by 14.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 342,934 shares of the company’s stock valued at $3,999,000 after purchasing an additional 43,471 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of Sotera Health by 125.5% during the 1st quarter. Acadian Asset Management LLC now owns 25,192 shares of the company’s stock worth $293,000 after purchasing an additional 14,018 shares in the last quarter. Creative Planning grew its stake in shares of Sotera Health by 15.3% in the 2nd quarter. Creative Planning now owns 20,186 shares of the company’s stock valued at $224,000 after buying an additional 2,673 shares during the period. Finally, Invesco Ltd. grew its stake in shares of Sotera Health by 4.2% in the 2nd quarter. Invesco Ltd. now owns 319,156 shares of the company’s stock valued at $3,549,000 after buying an additional 12,758 shares during the period. Institutional investors and hedge funds own 91.03% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Sotera Health in a report on Friday, June 5th. They issued a “buy” rating and a $20.00 price objective for the company. JPMorgan Chase & Co. upped their price target on shares of Sotera Health from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Friday. Citigroup raised their price target on shares of Sotera Health from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Friday. Barclays lifted their price target on shares of Sotera Health from $19.00 to $22.00 and gave the stock an “overweight” rating in a report on Friday. Finally, Piper Sandler reissued an “overweight” rating and issued a $25.00 price objective (up from $22.00) on shares of Sotera Health in a research note on Friday. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $21.50.

About Sotera Health

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.